NF
Nan Fung Trinity (Hk) Ltd
13F filer · CIK 0001781880Reported Jul 24, 2026
Net seller this quarter
13F portfolio value$1.01BU.S. long equity reported on 13F
Positions464 new · 14 closed
Net flow last quarter-$41.1MBuys minus sells
Top 10 positions weight39.5%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Jul 24, 202646 positions | |||||
| $67.8M | 6.69% | 0.01% | -27.8% | Q2 2023 | |
| $52M | 5.13% | 0.26% | +7.5% | Q1 2024 | |
| $48.2M | 4.76% | 0.18% | Not reported | Q2 2024 | |
| $40.9M | 4.04% | 0.14% | +202.7% | Q3 2025 | |
| $36.1M | 3.56% | 0.00% | -21.7% | Q2 2023 | |
| $35.2M | 3.48% | 0.01% | +37.4% | Q4 2025 | |
| $33.8M | 3.34% | 0.81% | +0.3% | Q4 2025 | |
| $29.6M | 2.92% | 0.24% | +37.0% | Q1 2026 | |
| $28.4M | 2.80% | 0.01% | -34.4% | Q4 2025 | |
| $28.3M | 2.80% | 0.04% | Not reported | Q1 2024 | |
| $27.4M | 2.71% | 0.00% | -20.2% | Q2 2025 | |
| $27.2M | 2.69% | 0.36% | Not reported | Q2 2025 | |
| $24.1M | 2.38% | 0.02% | +28.3% | Q3 2025 | |
| $22.6M | 2.23% | 0.85% | +6.2% | Q3 2025 | |
| $21M | 2.08% | Not reported | +145.8% | Q4 2019 | |
| $19.7M | 1.94% | 0.25% | Not reported | Q2 2025 | |
| $18.9M | 1.87% | 0.18% | +10.2% | Q3 2025 | |
| $16.6M | 1.63% | 0.04% | Not reported | Q4 2019 | |
| $16.3M | 1.61% | 0.11% | Not reported | Q4 2025 | |
| $15.9M | 1.57% | 0.16% | Not reported | Q4 2025 | |
| $15.8M | 1.56% | 0.00% | +35.8% | Q3 2023 | |
| $15.7M | 1.55% | 0.23% | Not reported | Q3 2025 | |
| $15.3M | 1.52% | 0.02% | Not reported | Q4 2025 | |
| $15.1M | 1.50% | 0.63% | Not reported | Q2 2025 | |
| $15M | 1.48% | 0.26% | Not reported | Q2 2025 | |
| $13.5M | 1.33% | 0.08% | New | Q2 2026 | |
| $12.9M | 1.27% | 1.32% | +10.3% | Q3 2025 | |
| $12.6M | 1.25% | 0.14% | Not reported | Q3 2025 | |
| $12.3M | 1.22% | 0.02% | +31.5% | Q1 2025 | |
| $12.2M | 1.20% | Not reported | +31.5% | Q2 2026 | |
| $11.9M | 1.18% | 1.19% | New | Q2 2026 | |
| $11.7M | 1.16% | 0.02% | New | Q2 2026 | |
| $11.3M | 1.12% | 0.90% | Not reported | Q4 2025 | |
| $10.9M | 1.07% | 0.21% | Not reported | Q4 2025 | |
| $8.08M | 0.80% | 0.08% | Not reported | Q3 2023 | |
| $7.9M | 0.78% | 0.18% | Not reported | Q3 2025 | |
| $6.86M | 0.68% | 0.19% | -2.4% | Q4 2023 | |
| $6.58M | 0.65% | 0.03% | Not reported | Q2 2025 | |
| $5.91M | 0.58% | 1.67% | Not reported | Q2 2025 | |
| $5.65M | 0.56% | 0.08% | Not reported | Q3 2023 | |
| $5.32M | 0.53% | 0.17% | Not reported | Q4 2025 | |
| $4.7M | 0.46% | 0.63% | -14.2% | Q2 2025 | |
| $4.5M | 0.44% | 0.18% | New | Q2 2026 | |
| $4.34M | 0.43% | Not reported | Not reported | Q3 2023 | |
| $3.49M | 0.34% | 0.36% | Not reported | Q4 2025 | |
| $2.85M | 0.28% | 0.35% | +61.9% | Q2 2025 | |
| Q1 2026Reported May 5, 202655 positions | |||||
| $44.4M | 4.87% | 0.24% | +20.5% | Q1 2024 | |
| $42.5M | 4.66% | 0.18% | +47.4% | Q2 2024 | |
| $41.8M | 4.59% | 0.81% | +30.7% | Q4 2025 | |
| $40.1M | 4.41% | 0.00% | +18.2% | Q2 2023 | |
| $33.7M | 3.70% | 0.00% | -7.8% | Q2 2025 | |
| $32.9M | 3.61% | 0.01% | Not reported | Q2 2023 | |
| $28.2M | 3.09% | 0.01% | +98.6% | Q4 2025 | |
| $28.1M | 3.08% | 0.04% | Not reported | Q1 2024 | |
| $23.9M | 2.63% | 0.01% | +54.9% | Q4 2025 | |
| $21.5M | 2.36% | 0.38% | +2.3% | Q2 2025 | |
| $19.2M | 2.11% | 0.04% | Not reported | Q4 2019 | |
| $19M | 2.08% | 0.01% | Not reported | Q1 2025 | |
| $18.7M | 2.05% | 0.01% | Not reported | Q3 2025 | |
| $16.9M | 1.86% | 0.25% | -11.1% | Q2 2025 | |
| $16.3M | 1.79% | 0.11% | +99.1% | Q4 2025 | |
| $15.8M | 1.74% | 0.02% | +15.8% | Q4 2025 | |
| $15.6M | 1.72% | 0.63% | Not reported | Q2 2025 | |
| $15.6M | 1.72% | 0.00% | +41.4% | Q3 2023 | |
| $15M | 1.65% | 0.05% | -31.7% | Q3 2025 | |
| $14.7M | 1.62% | 0.17% | New | Q1 2026 | |
| $14.4M | 1.58% | 0.26% | +9.2% | Q2 2025 | |
| $14.4M | 1.58% | 0.16% | +13.7% | Q3 2025 | |
| $14M | 1.54% | 0.24% | +8.5% | Q3 2025 | |
| $13.7M | 1.50% | 0.16% | Not reported | Q4 2025 | |
| $13.6M | 1.50% | 0.89% | +24.6% | Q3 2025 | |
| $12.1M | 1.33% | 0.52% | Not reported | Q3 2023 | |
| $11.8M | 1.30% | 0.21% | +28.5% | Q4 2025 | |
| $11.7M | 1.29% | 0.02% | +10.9% | Q3 2023 | |
| $11.1M | 1.22% | 0.14% | Not reported | Q3 2025 | |
| $11M | 1.21% | 0.03% | Not reported | Q2 2020 | |
| $10.1M | 1.10% | 0.90% | +9.1% | Q4 2025 | |
| $9.65M | 1.06% | 0.00% | Not reported | Q3 2025 | |
| $8.76M | 0.96% | 0.34% | Not reported | Q3 2024 | |
| $8.7M | 0.95% | Not reported | Not reported | Q4 2019 | |
| $8.66M | 0.95% | 1.20% | +10.4% | Q3 2025 | |
| BTBCAXBicara Therapeutics Inc. | $8.51M | 0.93% | 0.65% | +14.9% | Q2 2025 |
| $7.14M | 0.78% | 0.09% | -14.0% | Q2 2025 | |
| $6.8M | 0.75% | 0.07% | Not reported | Q3 2024 | |
| $6.52M | 0.72% | 0.03% | +28.3% | Q2 2025 | |
| $6.33M | 0.69% | 0.08% | Not reported | Q3 2023 | |
| $5.95M | 0.65% | 0.18% | Not reported | Q3 2025 | |
| $5.02M | 0.55% | 0.19% | Not reported | Q4 2023 | |
| $4.29M | 0.47% | 1.68% | Not reported | Q2 2025 | |
| STSLNOSoleno Therapeutics Inc | $4.22M | 0.46% | 0.24% | +1.8% | Q2 2025 |
| $4.17M | 0.46% | Not reported | Not reported | Q3 2023 | |
| $3.74M | 0.41% | 0.08% | Not reported | Q3 2023 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $3.11M | 0.34% | 0.30% | Not reported | Q2 2025 |
| $2.88M | 0.32% | 0.88% | -9.3% | Q2 2025 | |
| $2.82M | 0.31% | 0.77% | Not reported | Q4 2025 | |
| $2.74M | 0.30% | Not reported | -83.1% | Q2 2025 | |
| Q4 2025Reported Feb 4, 202669 positions | |||||
| $42.2M | 3.34% | 0.00% | +15.9% | Q4 2019 | |
| $38.6M | 3.06% | 0.20% | Not reported | Q1 2024 | |
| $36.3M | 2.88% | 0.00% | +18.7% | Q2 2023 | |
| $35.8M | 2.83% | Not reported | +11.1% | Q4 2019 | |
| $34.6M | 2.74% | 0.01% | +121.5% | Q2 2023 | |
| $31.5M | 2.50% | 0.00% | +49.8% | Q4 2024 | |
| $29.6M | 2.35% | 0.00% | Not reported | Q2 2025 | |
| $28.3M | 2.24% | 0.62% | New | Q4 2025 | |
| $27.6M | 2.19% | 0.12% | +8.6% | Q2 2024 | |
| $25.9M | 2.05% | 0.01% | Not reported | Q1 2025 | |
| $25.3M | 2.01% | 0.07% | Not reported | Q3 2025 | |
| $24.7M | 1.95% | Not reported | Not reported | Q1 2025 | |
| $23.9M | 1.89% | 0.04% | +57.7% | Q1 2024 | |
| $22.6M | 1.79% | 0.01% | +66.8% | Q3 2025 | |
| $21.3M | 1.69% | Not reported | +32.6% | Q2 2024 | |
| $18.6M | 1.48% | 0.04% | +35.2% | Q4 2019 | |
| $18M | 1.42% | Not reported | Not reported | Q2 2025 | |
| $18M | 1.42% | 0.11% | +15.6% | Q3 2023 | |
| $18M | 1.42% | 0.44% | +45.6% | Q2 2025 | |
| $17.4M | 1.38% | 0.02% | New | Q4 2025 | |
| $17.3M | 1.37% | 0.01% | New | Q4 2025 | |
| CTCDTXCidara Therapeutics, Inc. | $17M | 1.35% | 0.25% | New | Q4 2025 |
| $16.7M | 1.33% | 0.23% | New | Q4 2025 | |
| $16.6M | 1.31% | 0.81% | Not reported | Q4 2024 | |
| $16.4M | 1.30% | 0.01% | +5.4% | Q1 2025 | |
| $16.3M | 1.29% | 0.03% | Not reported | Q3 2024 | |
| $16.2M | 1.28% | 0.00% | New | Q4 2025 | |
| $15.8M | 1.25% | 0.29% | +24.7% | Q2 2025 | |
| $15.3M | 1.22% | 0.63% | +20.7% | Q2 2025 | |
| $15.3M | 1.22% | 0.01% | Not reported | Q2 2025 | |
| $15.3M | 1.21% | 0.14% | +11.8% | Q3 2025 | |
| $14.3M | 1.14% | 0.02% | New | Q4 2025 | |
| $14.3M | 1.13% | 0.16% | New | Q4 2025 | |
| $14.2M | 1.12% | 0.01% | -42.2% | Q1 2025 | |
| $12.8M | 1.01% | 0.00% | +20.6% | Q3 2025 | |
| $12.3M | 0.97% | 0.00% | Not reported | Q3 2023 | |
| $11.7M | 0.93% | 0.14% | +35.8% | Q3 2025 | |
| $11.6M | 0.92% | 0.24% | +599.3% | Q3 2025 | |
| $11.5M | 0.91% | 0.72% | +924.2% | Q3 2025 | |
| $10.2M | 0.81% | 0.83% | New | Q4 2025 | |
| $10.2M | 0.81% | 0.28% | +43.1% | Q2 2025 | |
| $10M | 0.79% | Not reported | Not reported | Q4 2019 | |
| $10M | 0.79% | 1.10% | +317.9% | Q3 2025 | |
| $9.41M | 0.75% | 0.35% | Not reported | Q3 2024 | |
| $8.53M | 0.68% | 0.02% | +36.4% | Q3 2023 | |
| $8.42M | 0.67% | 0.06% | New | Q4 2025 | |
| $8.23M | 0.65% | 0.08% | +33.7% | Q3 2023 | |
| $8.06M | 0.64% | 0.17% | New | Q4 2025 | |
| $7.88M | 0.62% | 0.18% | +172.4% | Q3 2025 | |
| $6.59M | 0.52% | 0.11% | +37.1% | Q2 2025 | |
| Q3 2025Reported Nov 4, 202562 positions | |||||
| $37.9M | 3.78% | 0.20% | +9.3% | Q1 2024 | |
| $34.6M | 3.45% | 0.00% | Not reported | Q4 2019 | |
| $32.5M | 3.24% | Not reported | -49.3% | Q4 2019 | |
| $30.6M | 3.05% | 0.00% | +25.8% | Q2 2023 | |
| $30.1M | 3.01% | 0.00% | +352.2% | Q2 2025 | |
| $26.7M | 2.66% | 0.01% | +9.2% | Q1 2025 | |
| $26.1M | 2.60% | 0.11% | Not reported | Q2 2024 | |
| $23.6M | 2.35% | Not reported | Not reported | Q1 2025 | |
| $23.2M | 2.32% | 0.07% | New | Q3 2025 | |
| $22.5M | 2.25% | 0.00% | +11.6% | Q4 2024 | |
| $22.3M | 2.22% | 0.01% | -42.1% | Q1 2025 | |
| $19M | 1.90% | 0.81% | Not reported | Q4 2024 | |
| $18.7M | 1.87% | 0.03% | Not reported | Q3 2024 | |
| $18.1M | 1.81% | Not reported | Not reported | Q2 2024 | |
| $16.8M | 1.68% | 0.03% | Not reported | Q4 2019 | |
| $16.8M | 1.67% | 0.01% | Not reported | Q1 2025 | |
| $16.7M | 1.67% | 0.03% | Not reported | Q1 2024 | |
| $16.3M | 1.62% | Not reported | Not reported | Q2 2025 | |
| $16M | 1.60% | 0.14% | Not reported | Q1 2024 | |
| $15.3M | 1.53% | 0.00% | New | Q3 2025 | |
| $15.2M | 1.52% | 0.09% | Not reported | Q3 2023 | |
| $14.7M | 1.46% | 0.10% | New | Q3 2025 | |
| $14.3M | 1.43% | 0.00% | Not reported | Q3 2023 | |
| MMRUSMerus N.V. | $14.2M | 1.41% | 0.20% | Not reported | Q2 2025 |
| $14.1M | 1.41% | 0.01% | Not reported | Q2 2025 | |
| $13.7M | 1.36% | 0.23% | -1.2% | Q4 2024 | |
| $12.3M | 1.23% | 0.08% | -29.1% | Q4 2024 | |
| $11.8M | 1.18% | 0.00% | Not reported | Q2 2023 | |
| $11.7M | 1.17% | 0.01% | New | Q3 2025 | |
| $11.5M | 1.14% | 0.30% | +6.5% | Q2 2025 | |
| TBTRMLTourmaline Bio, Inc. | $10.9M | 1.08% | 0.88% | Not reported | Q2 2025 |
| $9.63M | 0.96% | 0.23% | +7.3% | Q2 2025 | |
| $9.23M | 0.92% | 0.35% | Not reported | Q3 2024 | |
| $9.15M | 0.91% | 0.02% | Not reported | Q2 2025 | |
| $8.61M | 0.86% | 0.16% | New | Q3 2025 | |
| STSLNOSoleno Therapeutics Inc | $8.37M | 0.84% | 0.23% | +20.3% | Q2 2025 |
| VPVRNAVerona Pharma plc | $8.14M | 0.81% | 0.01% | -54.2% | Q2 2025 |
| $6.93M | 0.69% | 0.65% | +7.9% | Q2 2025 | |
| $6.78M | 0.68% | 0.06% | +94.9% | Q3 2023 | |
| $6.48M | 0.65% | 0.07% | Not reported | Q3 2024 | |
| $6.37M | 0.64% | 0.21% | Not reported | Q2 2025 | |
| $6.14M | 0.61% | Not reported | Not reported | Q3 2023 | |
| BTBCAXBicara Therapeutics Inc. | $6.08M | 0.61% | 0.70% | +12.3% | Q2 2025 |
| $5.74M | 0.57% | 0.01% | Not reported | Q3 2023 | |
| ATAKROAkero Therapeutics, Inc. | $5.25M | 0.52% | 0.14% | Not reported | Q2 2025 |
| $4.95M | 0.49% | 0.04% | New | Q3 2025 | |
| $4.61M | 0.46% | 0.53% | -51.0% | Q2 2020 | |
| $3.98M | 0.40% | 0.05% | -53.5% | Q3 2023 | |
| $3.76M | 0.37% | 0.08% | Not reported | Q2 2025 | |
| $3.27M | 0.33% | 0.07% | New | Q3 2025 | |
Premium opens every quarter this fund has filed